With the use of low-dose heparin, fetal survival of aPL pregnancies is 70-80%, but prematurity and intrauterine growth restriction are common. It is likely, but not proven, that dysregulated placental coagulation and resultant vasculopathy are the cause of fetal loss. Details of dysregulated coagulation remain to be described. Opportunities remain to determine the role of coagulopathy in repeated pregnancy loss, identify a critical event or window to which intervention might be directed, identify maternal (and fetal) characteristics other than aPL that determine fetal loss, describe toxicity profiles of current treatments, develop more specific, less toxic therapies, and describe long-term fetal and maternal outcomes.
LakasingL, PostonL.Adverse pregnancy outcome in the anti-phospholipid syndrome: focus for future research.Lupus1997; 6: 681–684.
2.
LimaF. A study of sixty pregnancies in patients with the antiphospholipid syndrome.Clin Exp Rheumatol1996; 14: 131–136.
3.
RaiR, CohenH, DaveM, ReganL.Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).BMJ1997; 314: 253–257.
4.
KuttehWH.Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.Am J Obstet Gynecol1996; 174: 1584–1589.
5.
LynchA. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study.Ann Intern Med1994; 120: 470–475.
6.
KuttehWH.Antiphospholipid antibodies and reproduction.J Reprod Immunol1997; 35: 151–171.
7.
YetmanDL, KuttehWH.Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies.Fertil Steril1996; 66: 540–546.
8.
BranchDW. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.Obstet Gynecol1992; 80: 614–620.
9.
StephansonMD.Frequency of factors associated with habitual abortion in 197 couples.Fertil Steril1996; 66: 24–29.
10.
MacLeanMA. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages.Br J Obstet Gynecol1994; 101: 103–106.
11.
LaskinCA. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.N Engl J Med1997; 337: 148–153.
12.
KatanoK. Postpartum thrombosis after a successful pregnancy in a recurrent aborter positive for antiphospholipid antibodies.Gynecol Obstet Invest1998; 45: 81–84.
13.
GevaE. Circulating autoimmune antibodies may be responsible for implantation failure in in vitro fertilization.Fertil Steril1994; 62: 802–806.
14.
BirkenfeldA. Incidence of autoimmune antibodies in failed embryo transfer cycles.Am J Reprod Immunol1994; 31: 65–68.
15.
KaiderBD, PriceDE, RoussevRG, CoulamCB.Antiphospholipid antibody prevalence in patients with IVF failure.Am J Reprod Immunol1996; 35: 388–393.
16.
BirdsallMA. Antiphospholipid antibodies in women having in-vitro fertilization.Hum Reprod1996; 11: 1185–1189.
17.
Ramsey-GoldmanR. Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus.Am J Epidemiol1993; 138: 1057–1069.
18.
AokiK.. Clinical significance of beta 2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: correlation with conventional antiphospholipid antibody detection systems.Am J Obstet Gynecol1995; 172: 926–931.
MagidMS. Placental pathology in systemic lupus erythematosus: a prospective study.Am J Obstet Gynecol, 1998, in press.
21.
KatanoK. Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera.Lupus1995; 4: 304–308.
22.
PeacemanAM, RehnbergKA.The effect of aspirin and indomethacin on prostacycline and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant.Am J Obstet Gynecol1995; 173: 1391–1396.
23.
Di SimoneN. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera.Hum Reprod1997; 12: 2061–2065.
24.
SammaritanoLR. Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein.J Clin Immunol1992; 12: 27–35.
25.
RandJH. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi.Am J Obstet Gynecol1997; 177: 918–923
26.
RandJH. Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism.N Engl J Med1997; 337: 154–160.
27.
LaRosaL. Beta-2-glycoprotein I and placental anticoagulant protein 1 in placentae from patients with antiphospholipid antibody syndrome.J Rheumatol1994; 21: 1684–1693.
28.
ZiporenL, BlankM, ShoenfeldY.Animal models for antiphospholipid syndrome in pregnancy.Rheum Dis Clin North Am1997; 23: 99–117.
29.
GharaviAE, SammaritanoLR, BovastroSL, WilsonWL.Specificities and characteristics of beta-2-glycoprotein I-induced antiphospholipid antibodies.J Lab Clin Med1995; 125: 775–778.
30.
SthoegerZM. Anticardiolipin, but not the 16/6 Id anti-DNA antibody induces pregnancy failure.Immunol Lett1996; 49: 117–122.
31.
PionaA. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice.Scand J Immunol1995; 41: 427–432.
32.
IkematsuW. Human anticardiolipin mAbs cause placental necrosis and fetal loss in BALB/c mice.Arthritis Rheum1998; 41: 1026–1039.
33.
BranchDW, SilverRM.Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss.Lupus1996; 5: 409–413.
34.
VogtE, NgAk, RoteNS.A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice.Am J Obstet Gynecol1996; 174: 700–707.
35.
SansonBJ. The risk of abortion and stillbirth in antithrombin-,protein C-, and protein S-deficient women.Thromb Haemost1996; 75: 387–388.
36.
ShoenfeldY, FishmanP.Role of IL-3 in the antiphospholipid syndrome.Lupus1994; 3: 259–261.
37.
SammaritanoLR. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis.Arthritis Rheum1997; 40: 1998–2006
38.
NelsonJL. Maternal—fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis.N Engl J Med1993; 329: 466–471.
39.
BrennanP, PaytonT, OllierB, SilmanA.Maternal exposure to paternal HLA does not explain the postpartum increase in rheumatoid arthritis.Gen Epidemiol1996; 13: 411–418.
40.
BianchiDW. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum.Proc Natl Acad Sci USA1996; 93: 705–708.
41.
NelsonJL. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma.Lancet1998; 351: 559–562.
42.
ArtlettCM, SmithJB, JimenezSA.Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis.N Engl J Med1998; 338: 1186–1191.
43.
MullinaxGL, MullinaxF.Chimerism in lupus erythematosus. Identification of offspring-derived cells in patients with systemic lupus erythematosus.Lupus1998; 7: s14
44.
KuttehWH, ErmelLD.A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin.Am J Reprod Immunol1996; 35: 402–407.
45.
ErmelLD, MarshburnPB, KuttehWH.Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL).Am J Reprod Immunol1995; 33: 14–20.
46.
BlankM. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome.Arthritis Rheum1998; 41: 224–232.
47.
KanaiY. Therapeutic plasmapheresis for the treatment of pregnant systemic lupus erythematosus patients with antiphospholipid antibodies.Lupus1998; 7: s114
48.
HargerJH. Low-dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants.J Perinatol1995; 15: 463–469.
49.
BarbourLA. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry.Am J Obstet Gynecol1994; 170: 862–869.
50.
RossG, SammaritanoLR, NassR, LockshinMD.Learning disabilities in offspring of women with systemic lupus erythematosus.Arthritis Rheum1993; 36: s87.
51.
McAllisterDL. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends.J Int Neuropsychol Soc1997; 3: 370–6.
